Table 1.

Incidence of CBF-AML, as well as the cytogenetic subgroups of inv(16) AML, and t(8;21) AML, diagnosed between 2000-2010 in patients 15-84 years old at diagnosis. The incidence of all sub-types of AML reported to SEER is included as a reference.

	AML (all subtypes)		CBF-AML			inv(16) subgroup			t(8;21) subgroup
	No. of patients	Incidence rate†	No. of patients	Incidence rate†	Median age at diagnosis	No. of patients	Incidence rate†	Median age at diagnosis	No. of patients	Incidence rate†	Median age at diagnosis
All patients, 15-84 yr.	27665	4.11	777	0.11	54	320	0.05	50	457	0.07	57
Age Group
15-44 yr.	4811	1.24	254	0.06	31	128	0.03	33	126	0.03	28
45-64 yr.	8584	3.81	285	0.13	54	115	0.05	55	170	0.08	53
65-74 yr.	6659	12.35	137	0.25	69	46	0.08	69	91	0.17	69
75-84 yr.	7611	20.87	101	0.28	79	31	0.09	77	70	0.19	80
Gender
Male	15209	4.99	441	0.14	56	186	0.06	51	255	0.08	60
Female	12456	3.43	336	0.09	51	134	0.04	49	202	0.06	52
Race††
White	23132	4.26	632	0.12	56	277	0.05	52	355	0.06	59
Black	2305	3.40	57	0.07	52	12	0.02	46	45	0.06	52
Other	2102	3.23	87	0.12	47	31	0.04	41	56	0.08	49
Ethnicity
Non-Hispanic	24632	4.18	673	0.11	56	269	0.05	52	404	0.07	58
Hispanic	3033	3.44	104	0.09	44	51	0.04	39	53	0.05	46

^†Incidence rate was adjusted to the US 2000 standard population and is per 100 000 people

^††Other includes American Indian, Alaska Native, Asian, or Pacific Islander. The patient in CBF AML (n=1) and overall AML (n=126) with unknown race is not listed.